🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesEchocardiographic changes on GLP-1 — my results so far Page 2

Echocardiographic changes on GLP-1 — my results so far

james_edin Sat, Feb 22, 2025 at 4:47 PM 13 replies 1,554 viewsPage 2 of 3
sarah.morrison
VIP Member
3,212
14,567
Jan 2024
California
Online
Feb 22, 2025 at 7:33 PM#6
DataDave said:
Vitamin deficiency cascade with cardiovascular risk: after 6+ months of reduced food intake, I developed a subtle but important pattern: low B12 →…

I read this differently from DataDave, on substance rather than tone. The "earlier than weight loss explains" argument is weaker than this thread makes it sound. Blood pressure and inflammatory markers move fast and are downstream of early weight loss, so the mechanism is not as cleanly separable as the summaries imply.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

17 20josh_phd_bmore, roxy_nash, tony_orlando and 14 others
Reply Quote Save Share Report
SleepDoc_PDX
Member
289
1,234
Sep 2024
Portland, OR
Feb 22, 2025 at 8:38 PM#7
james_edin said:
My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

6 month update on cardiovascular risk: down 42 lbs, off blood pressure meds, A1C normalized. Genuinely life-changing.

18 21hank_denver, carlos_SATX, sophie_paris and 15 others
Reply Quote Save Share Report
NurseKim_ATL
Senior Member
1,678
7,234
Feb 2024
Atlanta, GA
Feb 22, 2025 at 9:43 PM#8
sarah.morrison said:
The "earlier than weight loss explains" argument is weaker than this thread makes it sound.

Metabolic syndrome resolution on cardiovascular risk: I went from meeting 5 of 5 diagnostic criteria to meeting ZERO after 13 months of treatment.

The 5 criteria (and my journey):

  1. Waist circumference: 52" → 34" ✅ Resolved
  2. Triglycerides: 236 → 96 ✅ Resolved
  3. HDL: 36 → 58 ✅ Resolved
  4. Blood pressure: 146/94 → 119/73 ✅ Resolved
  5. Fasting glucose: 116 → 88 ✅ Resolved

Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.

19 22ingrid_STO, pete_nash, hank_denver and 16 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
pam_columbus
Member
312
1,345
Aug 2024
Columbus, OH
Feb 22, 2025 at 10:48 PM#9

Following on from Dr.BariatricHTX — and this may be the naive question:

What did you change at the same time, and can you separate the two now?

Last edited: Feb 23, 2025 at 4:48 AM
20 23tammy_FL, Dr.LipidDallas, alex_tucson and 17 others
Reply Quote Save Share Report
james_edin
Member
289
1,234
Sep 2024
Edinburgh, UK
Feb 23, 2025 at 4:01 AM#10
NurseKim_ATL said:
Metabolic syndrome resolution on cardiovascular risk: I went from meeting 5 of 5 diagnostic criteria to meeting ZERO after 13 months of treatment.

NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).

From SELECT trial: MACE at 39 months — 6.5% semaglutide vs 8.0% placebo. ARR = 1.5%. NNT = 67 over 3.3 years.

Compare to established therapies:

InterventionNNTTimeframe
Semaglutide (MACE)673.3 years
Statins primary prevention (MI)~1005 years
Aspirin secondary prevention~772 years

These NNTs are clinically meaningful and comparable to accepted cardiovascular interventions.

Last edited: Feb 23, 2025 at 6:01 AM
10 8bbq_ray_KC, oliver_london, tane_welly and 7 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register